Concepts (93)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spironolactone | 4 | 2012 | 36 | 1.430 |
Why?
|
| Aldosterone | 6 | 2012 | 62 | 0.970 |
Why?
|
| Kidney | 5 | 2012 | 322 | 0.770 |
Why?
|
| Hypertension | 7 | 2007 | 770 | 0.530 |
Why?
|
| Nitric Oxide | 9 | 2019 | 287 | 0.500 |
Why?
|
| Cyclooxygenase 1 | 1 | 2012 | 11 | 0.440 |
Why?
|
| Losartan | 3 | 2007 | 31 | 0.430 |
Why?
|
| Cyclooxygenase 2 | 1 | 2012 | 92 | 0.420 |
Why?
|
| Rats, Inbred Dahl | 6 | 2012 | 30 | 0.410 |
Why?
|
| Sodium Chloride, Dietary | 2 | 2011 | 40 | 0.400 |
Why?
|
| Blood Pressure | 9 | 2012 | 613 | 0.380 |
Why?
|
| Simvastatin | 2 | 2007 | 28 | 0.370 |
Why?
|
| Antioxidants | 2 | 2019 | 386 | 0.360 |
Why?
|
| Epoprostenol | 7 | 2012 | 21 | 0.350 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2010 | 157 | 0.350 |
Why?
|
| Membrane Proteins | 1 | 2012 | 486 | 0.330 |
Why?
|
| Rats | 10 | 2012 | 3261 | 0.310 |
Why?
|
| Enalapril | 1 | 2006 | 6 | 0.280 |
Why?
|
| Endothelium, Vascular | 2 | 2007 | 229 | 0.280 |
Why?
|
| Cyclic N-Oxides | 1 | 2006 | 17 | 0.280 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2006 | 64 | 0.270 |
Why?
|
| Oxidative Stress | 6 | 2019 | 874 | 0.240 |
Why?
|
| Dinoprost | 3 | 2011 | 22 | 0.220 |
Why?
|
| Angiotensin II | 5 | 2007 | 92 | 0.220 |
Why?
|
| Blotting, Western | 3 | 2019 | 834 | 0.210 |
Why?
|
| Acetophenones | 2 | 2012 | 7 | 0.210 |
Why?
|
| Heart Rate | 5 | 2012 | 248 | 0.210 |
Why?
|
| Systole | 2 | 2012 | 65 | 0.210 |
Why?
|
| Diet | 1 | 2007 | 747 | 0.200 |
Why?
|
| Thromboxane A2 | 5 | 2007 | 18 | 0.180 |
Why?
|
| Trabecular Meshwork | 1 | 2019 | 11 | 0.180 |
Why?
|
| Animals | 10 | 2012 | 14307 | 0.160 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 112 | 0.160 |
Why?
|
| Glaucoma | 1 | 2019 | 87 | 0.160 |
Why?
|
| Male | 9 | 2012 | 18870 | 0.140 |
Why?
|
| Dinoprostone | 2 | 2012 | 57 | 0.120 |
Why?
|
| Body Weight | 3 | 2011 | 404 | 0.110 |
Why?
|
| Superoxides | 3 | 2007 | 51 | 0.110 |
Why?
|
| Vasoconstrictor Agents | 1 | 2012 | 38 | 0.110 |
Why?
|
| Urinalysis | 1 | 2011 | 31 | 0.100 |
Why?
|
| Proteinuria | 1 | 2011 | 48 | 0.100 |
Why?
|
| Antihypertensive Agents | 2 | 2004 | 284 | 0.100 |
Why?
|
| Sodium | 1 | 2011 | 101 | 0.100 |
Why?
|
| Protein Subunits | 1 | 2011 | 85 | 0.100 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 2 | 2007 | 37 | 0.090 |
Why?
|
| Rats, Inbred SHR | 2 | 2007 | 31 | 0.090 |
Why?
|
| Immunohistochemistry | 1 | 2012 | 859 | 0.090 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2007 | 77 | 0.090 |
Why?
|
| Drug Therapy, Combination | 2 | 2006 | 217 | 0.080 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2007 | 11 | 0.080 |
Why?
|
| Sodium, Dietary | 1 | 2007 | 25 | 0.080 |
Why?
|
| Treatment Outcome | 3 | 2006 | 1349 | 0.080 |
Why?
|
| Dietary Fats | 1 | 2007 | 115 | 0.070 |
Why?
|
| Spin Labels | 1 | 2006 | 8 | 0.070 |
Why?
|
| Sodium Chloride | 1 | 2006 | 52 | 0.070 |
Why?
|
| Lipids | 1 | 2007 | 222 | 0.070 |
Why?
|
| Disease Models, Animal | 3 | 2006 | 1300 | 0.070 |
Why?
|
| Drug Synergism | 1 | 2006 | 171 | 0.070 |
Why?
|
| Gene Expression Regulation | 1 | 2010 | 968 | 0.060 |
Why?
|
| Amlodipine | 1 | 2004 | 21 | 0.060 |
Why?
|
| Plant Oils | 1 | 2002 | 17 | 0.060 |
Why?
|
| Angiotensin I | 1 | 2002 | 7 | 0.050 |
Why?
|
| Salts | 1 | 2002 | 15 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2002 | 298 | 0.040 |
Why?
|
| E-Selectin | 1 | 2019 | 19 | 0.040 |
Why?
|
| Aorta | 3 | 2005 | 161 | 0.040 |
Why?
|
| Interleukin-1alpha | 1 | 2019 | 17 | 0.040 |
Why?
|
| Cyclic GMP | 3 | 2004 | 44 | 0.040 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2019 | 63 | 0.040 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2019 | 91 | 0.040 |
Why?
|
| Glutathione | 3 | 2004 | 160 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2004 | 1534 | 0.030 |
Why?
|
| Thromboxane B2 | 2 | 2004 | 8 | 0.030 |
Why?
|
| Cyclic AMP | 2 | 2004 | 125 | 0.030 |
Why?
|
| Buthionine Sulfoximine | 2 | 2003 | 10 | 0.030 |
Why?
|
| Enzyme Inhibitors | 2 | 2003 | 396 | 0.020 |
Why?
|
| Prostaglandins | 1 | 2005 | 25 | 0.020 |
Why?
|
| Mesenteric Arteries | 1 | 2005 | 18 | 0.020 |
Why?
|
| Vasoconstriction | 1 | 2005 | 40 | 0.020 |
Why?
|
| Vasodilator Agents | 1 | 2005 | 54 | 0.020 |
Why?
|
| Acetylcholine | 1 | 2005 | 68 | 0.020 |
Why?
|
| Organ Size | 1 | 2005 | 148 | 0.020 |
Why?
|
| Second Messenger Systems | 1 | 2004 | 14 | 0.020 |
Why?
|
| Myocardium | 1 | 2005 | 224 | 0.010 |
Why?
|
| F2-Isoprostanes | 1 | 2003 | 20 | 0.010 |
Why?
|
| Models, Cardiovascular | 1 | 2003 | 53 | 0.010 |
Why?
|
| Computer Graphics | 1 | 2002 | 16 | 0.010 |
Why?
|
| Isoprostanes | 1 | 2002 | 14 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2002 | 105 | 0.010 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 1 | 2002 | 2 | 0.010 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2002 | 60 | 0.010 |
Why?
|
| Time Factors | 1 | 2002 | 1681 | 0.010 |
Why?
|
| Humans | 1 | 2019 | 34853 | 0.010 |
Why?
|